The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Patients with ERBB2-positive breast cancer and CNS-only metastasis are at a high risk for CNS-related death but have longer overall survival than those with concomitant extracranial metastases.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...

A comparison of real-world outcomes by mismatch repair status in patients with stage II/III rectal cancer in the Netherlands. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

(HealthDay)—For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with ...

A global comparative study on real-world clinical and genomic differences in advanced biliary tract cancer. Extra-hepatic (ehCCA) and intra-hepatic cholangiocarcinomas (iCCA): A genomic landscape ...